Welcome back,

Tag : GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS

CONFERENCE UPDATE

Semaglutide improves walking capacity and QoL in patients with symptomatic PAD and T2D: Results from the phase 3b STRIDE trial